


Evolving Landscape of Stage III NSCLC

Kristin Higgins, MD Acting Full Professor, Dept of Radiation Oncology Medical Director and Vice Chair of Clinical Research Winship Cancer Institute of Emory University

Shifting Paradigms in Stage III NSCLC?

CRT + consolidative Immunotherapy




Neoadj Chemo IO + Surgery

2017- First PACIFIC publication

2022 – Checkmate 816

5 yr PACIFIC Overall Survival Data

Updated OS (ITT)



Data cutoff: 11 January 2021 (median follow-up: all patients, 34.2 months [range, 0.2–74.7]; censored patients, 61.6 months [range, 0.4–74.7]). 1. Antonia SJ, et al. New Engl J Med 2018;379:2342–50; 2. European Medicines Agency. Durvalumab (Imfinzi). Summary of product characteristics 2020. Available from: https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf 5. [Accessed April 2021]


CI, confidence interval; HR, hazard ratio; ITT, intent-to-treat; OS, overall survival


Spigel DR et al. 2021 ASCO Annual Meeting. Abstract 8511. Spigel DR et al. J Clin Oncol. 2022;40(12):1301-1311.

J




Resectable vs. Unresectable?






LUNG-ART Trial Schema

 Randomized phase III trial comparing post-operative RT to no post-op RT in patients with completely resected NSCLC and N2 involvement



- Primary endpoints: DFS
- Secondary endpoints including toxicity (cardiopulmonary), local control, OS, patterns of recurrence, second cancers


LUNG-ART Disease Free Survival



EMORY

WINSHIP CANCER

A Cancer Center Designated by the National Cancer Institute



LUNG-ART DFS Components


	PORT group (n=252)	Control group (n=249)
All disease-free survival events	144	152
Relapses and metastases	123 (85%)	144 (95%)
Mediastinal relapse	36 (25%)	70 (46%)
Brain metastasis	34 (24%)	27 (18%)
Extracranial metastasis	71 (49%)	71 (47%)
Death	21 (15%)	8 (5%)
Causes of death		
Cardiopulmonary	11 (8%)	0
Non-cancer related	0	1 (1%)
PORT toxicity	2 (1%)	0
Progression	1(1%)	0
Second primary cancer	4 (3%)	2 (1%)
Vascular	0	1 (1%)
Unknown	3 (2%)	4 (3%)

Data are n (%), regarding the number of patients with event. Patients can have several different events at the same time. PORT=postoperative radiotherapy.

Table 3: Disease-free survival events

Proton Beam Radiation Therapy in Patients with Resected N2 Non-Small Cell Lung Cancer





Winship Trial RAD5621-22; PIs: Kesarwala/Stokes/Buchwald; Funding: Winship Invest\$



- Multi-station N2 and stage IIIB included in many preop chemo IO studies
- Do these pts benefit from surgery?

~20% of pts don't make it to resection → what is ultimate clinical outcome for these patients?

Controversies in Unresectable Stage III NSCLC


- Immunotherapy in patients with PD-L1 negative tumors?
- Immunotherapy in patients with driver mutations?
- Treatment strategy for ECOG PS 2 patients?
- Best treatment for recurrent disease?
 - Distant recurrence post-Pacific
 - $_{\odot}$ Local only recurrence

	No. of Events / No.			Unstratified HR
Group	Durvalumab	Placebo		(95% CI)
All patients	264/476 (55.5)	155/237 (65.4)		0.72 (0.59 to 0.87)
Sex				
Male	192/334 (57.5)	112/166 (67.5)		0.75 (0.59 to 0.95)
Female	72/142 (50.7)	43/71 (60.6)	+	0.64 (0.44 to 0.94)
Age at random assignment	And the second second second	And the second second		
< 65 years	130/261 (49.8)	79/130 (60.8)	⊢ ●−−−1	0.66 (0.50 to 0.87)
≥ 65 years	134/215 (62.3)	76/107 (71.0)		0.79 (0.60 to 1.05)
Smoking status				
Smoker	244/433 (56.4)	140/216 (64.8)		0.75 (0.61 to 0.93)
Nonsmoker	20/43 (46.5)	15/21 (71.4)		0.42 (0.21 to 0.82)
NSCLC disease stage	Sector and the sector	and a series of the series of		and the second
IIIA	136/252 (54.0)	91/125 (72.8)	———	0.61 (0.47 to 0.80)
IIIB	121/212 (57.1)	61/107 (57.0)		0.86 (0.63 to 1.17)
Tumor histologic type				
Squamous	138/224 (61.6)	67/102 (65.7)	H	0.82 (0.61 to 1.09)
All other	126/252 (50.0)	88/135 (65.2)		0.62 (0.47 to 0.81)
Best response to prior treatment	t.			
Complete response	6/9 (66.7)	3/7 (42.9)		Not calculated ^a
Partial response	118/237 (49.8)	68/112 (60.7)		0.71 (0.52 to 0.95)
Stable disease	135/223 (60.5)	81/115 (70.4)	H	0.70 (0.53 to 0.92)
Prior chemotherapy type				
Gemcitabine-based	5/9 (55.6)	2/5 (40.0)	· · · · · · · · · · · · · · · · · · ·	Not calculated ^a
Non-gemcitabine-based	259/467 (55.5)	153/232 (65.9)	H	0.70 (0.58 to 0.86)
Cisplatin	134/266 (50.4)	81/129 (62.8)	H	0.65 (0.50 to 0.86)
Carboplatin	121/199 (60.8)	69/102 (67.6)		0.81 (0.60 to 1.09)
Cisplatin and carboplatin	6/8 (75.0)	4/5 (80.0)		Not calculated ^a
Last radiation to random assign	ment		6	
< 14 days	64/120 (53.3)	43/62 (69.4)	—	0.54 (0.37 to 0.80)
≥ 14 days	200/356 (56.2)	112/175 (64.0)		0.79 (0.63 to 1.00)
WHO PS				
0 – Normal	121/234 (51.7)	65/114 (57.0)		0.84 (0.62 to 1.14)
1 - Restricted ^b	143/242 (59.1)	90/123 (73.2)		0.62 (0.47 to 0.80)
Region				
Asia	54/109 (49.5)	37/68 (54.4)	1	0.79 (0.52 to 1.20)
Europe	125/217 (57.6)	64/102 (62.7)		0.84 (0.62 to 1.14)
North and South America	85/150 (56.7)	54/67 (80.6)		0.47 (0.34 to 0.67)
Race				
White	200/337 (59.3)	110/157 (70.1)		0.72 (0.57 to 0.91)
Black or African American	5/12 (41.7)	2/2 (100)		Not calculated ^a
Asian	56/120 (46.7)	39/72 (54.2)	100 CON	0.73 (0.48 to 1.09)
Uther	3/6 (50.0)	4/6 (60.7)		Not calculated
EGFR or ALK aberration status				
Positive ^d	17/29 (58.6)	8/14 (57,1)	1	0.85 (0.37 to 1.97)
Negative	166/317 (52.4)	109/165 (66.1)		0.66 (0.52 to 0.84)
Unknown	81/130 (62.3)	38/58 (65.5)		0.85 (0.57 to 1.24)
PD-L1 expression level	and the law of	ani an Innini		and fores to start
≥ 25%	51/115 (44.3)	27/44 (61.4)		0.52 (0.32 to 0.82)
< 25%	111/187 (59.4)	64/105 (61.0)		0.90 (0.67 to 1.23)
Unknown	102/174 (58.6)	64/88 (72.7)		0.68 (0.50 to 0.93)
1%-24% (post hoc analysis)	52/97 (53.6)	29/47 (61.7)		0.73 (0.46 to 1.14)
	103/212 (48.6)	29/47 (61.7) 56/91 (61.5)		0.73 (0.46 to 1.14) 0.61 (0.44 to 0.85)
≥ 1% (post hoc analysis) < 1% (post hoc analysis)		35/58 (60.3)		1.15 (0.75 to 1.75)
< 178 (post noc analysis)	59/90 (65.6)	30/06 (00.3)		1.15 (0.75 (0 1.75)

0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.

Durvalumab Better Placebo Bette

LAURA Phase III, double-blind, randomized, placebo-controlled trial



Primary endpointPFS

Secondary endpoints

• PFS in patients with EGFR Ex19del or L858R mutation

Osimertinib (EGFR)

- PFS in patients with EGFR mutations Ex19del or L858R detectable in plasma-derived ctDNA
- Time to CNS PFS
- OS, ORR, DoR, DCR, tumor shrinkage, TTDM, TTD, PFS2, TFST, TSST
- Patients reported diseaserelated symptoms and HRQoL
- Incidence of adverse eventsPK


^aEx19del or L858R either alone or in combination with other EGFR mutations; ^b Actual enrollment; ^cRandomized within 6 weeks of completion of chemoradiation; ^dOsimertinib dosing schedule: 80 mg PO QD; ^eA protocol amendment has been made in the Clinical Study Protocol version 2 (February 18, 2020).

CNS = central nervous system; CRT = chemoradiation therapy; ctDNA = circulating tumor DNA; DCR = disease control rate; DoR = duration of response; EGFR = epidermal growth factor receptor; *EGFR*m =

Study NCT03521154. ClinicalTrials.gov website.

11

Immunotherapy Strategy for Stage III PS 2EMORY
WINSHIP
CANCER
INSTITUTESCHEMA\$1933



Study Chairs:

Raid Aljumaily, MD, Medical Oncology University of Oklahoma Health Sciences Center Stephenson Cancer Center raid-aljumaily@ouhsc.edu

Timur Mitin, MD, PhD, Radiation Oncology Department of Radiation Medicine Oregon Health and Science University Knight Cancer Institute mitin@ohsu.edu

Co-Chairs:

Roy H. Decker, MD, PhD – Radiation Oncology, Department of Therapeutic Radiology, Yale School of Medicine Antoinette Wozniak, MD – Medical Oncology Hillman Cancer Center, University of Pittsburgh Medical Center


ADDING to the PACIFIC Regimen



- Can we continue to reduce distant recurrence with IO combos?
- Will timing of IO impact survival?
- How to best optimize RT component?
 - Management of isolated local recurrence

Consolidative Durvalumab and Race

PACIFIC Trial: 14 African Americans (2%) Emory Experience: 57 African Americans, 2017-2021




PACIFIC-2: Study Design

Study Population

- Patients with unresectable, Stage III NSCLC
- All-comers (PD-L1 expression-agnostic)
- ECOG PS 0-1

Randomised N = 300 patients




Stratification

- Age (≤65, >65)
- Stage (IIIA vs IIIB/C)

- Primary Endpoints: ORR, PFS
- Key Secondary Endpoints: OS, OS24
- Treat to progression

KEYNOTE-799 (NCT03631784) Study Design



Primary Objectives

- ORR per RECIST v1.1 by BICR
- Proportion of patients with grade ≥3 pneumonitis^c

Secondary Objectives

• PFS per RECIST v1.1 by BICR, OS, and safety

BICR, blinded independent central review.

Statistical Analysis Details

• Efficacy and safety assessed in all patients as-treated

COHORT B (Nonsquamous NSCLC Only)


^a60 Gy in 30 daily 2-Gy fractions 5 days per week. ^bTreatment continued until cycle 17 was completed or until documented disease progression, unacceptable AEs, intercurrent illness that prevented further administration of treatment, or study withdrawal. Pembrolizumab therapy was discontinued permanently in patients who developed grade ≥3 or recurrent grade 2 pneumonitis. ^cPer National Cancer Institute Common Terminology Criteria for Adverse Events v4.0; includes immune-mediated AE of "pneumonitis." and the Medical Dictionary for Regulatory Activities (MedDRA) preferred term of "radiation pneumonitis."

COHORT A (Squamous and Nonsquamous NSCLC)

KEYNOTE-799 2-year update


N	Population	Regimen	ORR (%)	PFS, med (mos)	Pneumonitis G3+/Gr5
112	NSCLC	Ind CbP + Pembro Conc chemoRT + Pembro Consolidation Pembro	71.4	30.6 mos (55.3% 2 yr)	8/3.6
102	ns-NSCLC	Ind Cis/Pem + Pembro Conc Cis/Pem/RT + Pembro Consolidation Pembro	75.5	60.6% 2 yr	6.9/1.0

Progression-Free Survival and Overall Survival




Jabbour et al, ASTRO annual meeting 2022

EA 5181: Trial Schema




NCT04092283. Updated October 19, 2022. https://clinicaltrials.gov/ct2/show/NCT04092283

IO Combos: COAST Randomized Phase II




IO Combos: COAST Randomized Phase II



Herbst RS et al. J Clin Oncol. 2022; 40(29):3383-3393.


NRG-LU004: Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined With MEDI4736 (durvalumab) in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)



22


Exploratory: tumor tissue/blood biomarkers, microbiome, TMB, PD-L1 IHC

Amendment for LU004 (Approved by CTEP June 2023)



SKYSCRAPER-03:Tiragolumab + Atezolizumab in Stage III NSCLC

Study Schema



Stratification Factors:

- PD-L1 expression (<1% vs \geq 1%)
- Staging (IIIA vs IIIB vs IIIC)
- Histology (Squamous vs Non-Squamous)
- ECOG PS (0 vs 1)


Safety Run-in:

- iDMC review after a minimum of 24 patients (approximately 12 patients per arm) have completed 2 cycles of study treatment
- Enrollment will not be paused

Co-Primary Endpoints:

IRF-assessed PFS in the


- PD-L1 positive population
- ITT population



PI: Dr. Chuck Simone

- Control arm: chemoradiation to the primary and mediastinal disease (60 Gy/2 Gy) \rightarrow immunotherapy maintenance x 12 months
- Experimental arm: SBRT to the primary (standard BED ≥100 Gy dose regimen) → chemoradiation to mediastinal disease (60 Gy/2 Gy) → immunotherapy maintenance x 12 months
 - SBRT to primary tumor:
 - 3 fractions to 54 Gy (BED10 of 151.2 Gy) [peripheral]
 - 4 fractions to 50 Gy (BED10 of 112.5 Gy) [peripheral or central]
 - 5 fractions to 50 Gy (BED10 of 100 Gy) [central] or to 60 Gy (BED10 of 132 Gy) [peripheral or central]

NRG LU008 – SBRT to primary




Total volume of lung receiving 40 Gy = 332 cc (compared to 590 cc, 44% reduction) Total volume of lung receiving 20 Gy=922 cc (compared to1300 cc, 29% reduction) nstitute | Emory University Total volume of lung receiving 10 Gy=2168 cc (compared to 2360, 8% reduction)

26

Local Recurrence Post-PACIFIC: Re-irradiation with Proton Therapy


- 22 patients, 2019-2021 with in-field disease recurrence or second primary after definitive chemoradiation (45% received consolidative immunotherapy)
- Median time to re-treatment: 28 months
- 36% received concurrent chemotherapy with proton therapy, 18% received immunotherapy following proton therapy (median dose 60 Gy)
- Grade 3 toxicity 14% (2 pneumonitis, one dermatitis), No grade 4 or 5 toxicities



Re-irradiation with Proton Therapy

Variable	Initial Course Median (Range)	Initial Course BED for α/β = 3 (Range)	IMPT Median (Range)	IMPT BED for $\alpha/\beta = 3$ (Range)	Cumulative Median (Range)
Prescription Dose	60 Gy (45-70 Gy)		60 GyE (44-60 GyE)		120 GyE (89-130 GyE)
Lung V20 Gy (or GyE)	19% (1%-3%)		8% (2%-26%)		22% (7%-54%)
Lung V5 Gy (or GyE)	51% (4%-96%)		17% (3%-46%)		55% (13%-99%)
Mean Lung dose	12 Gy (1-20 Gy)	14 Gy (1-26 Gy)	4 GyE (1-14 GyE)	5 GyE (1-17 GyE)	17 GyE (5-33 GyE)
Heart V10 Gy (or GyE)	17% (0%-89%)		3% (0%-51%)		22% (4%-89%)
Mean Heart dose	6 Gy (1-25 Gy)	6 Gy (1-33 Gy)	1 GyE (0-24 GyE)	1 GyE (0-31 GyE)	9 GyE (2-54 GyE)
Max Spinal Cord dose	29 Gy (5-46 Gy)	40 Gy (5-86 Gy)	10 GyE (0-35 GyE)	11 GyE (0-50 GyE)	41 GyE (5-58 GyE)
Mean Esophagus dose	18 Gy (2-50 Gy)	21 Gy (2-72 Gy)	4 GyE (0-24 GyE)	4 GyE (0-31 GyE)	31 GyE (2-62 GyE)
Max Aorta dose	59 Gy (17-72 Gy)	107 Gy (36-130 Gy)	47 GyE (0-63 GyE)	93 GyE (0-147 GyE)	92 GyE (24-133 GyE)
Max Pulmonary Artery dose	57 Gy (0-69 Gy)	102 Gy (0-122 Gy)	47 GyE (0-62 GyE)	90 GyE (0-120 GyE)	87 GyE (0-127 GyE)
Max Proximal Bronchial Tree dose	64 Gy (8-70 Gy)	110 Gy (9-124 Gy)	63 GyE (6-64 GyE)	105 GyE (0-155 GyE)	110 GyE (13-129 GyE)
Max Brachial Plexus dose	34 Gy (0-71 Gy)	49 Gy (0-127 Gy)	7 GyE (0-62 GyE)	8 GyE (0-147 GyE)	37 GyE (0-132 GyE)
BED, biologically equivalent dose; IMPT, intensity modulated proton therapy.					

Conclusions



- Cure rates for locally advanced NSCLC are improving
- Innovation in this space is strong
- Enroll patients in clinical trials testing these novel therapies
- As new therapies come on-line, our practice patterns will need to evolve